Dual PPAR-α/γ agonists, like tesaglitazar, muraglitazar, and ragaglitazar have been associated with compound-specific safety, like nonreversible increases in serum creatinine, increase in cardiovascular events, and bladder tumors, respectively; the last one being validated in rodents (Wright et al., 2014). Here, PPARA is linked to urinary bladder neoplasm.